Sugi Predict

Sugi Predict / Compounds / SCHEMBL125187

SCHEMBL125187

SCHEMBL125187

Cc1cc2nc(-c3ccccn3)[nH]c2cc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CBFB Q13951 12/20 1.00
▸ METAP2 P50579 7/20 1.00
▸ METAP1 P53582 5/20 1.00
▸ NPC1 O15118 5/20 0.72
▸ RAB9A P51151 5/20 0.72
▸ PKM P14618 4/20 0.72
▸ LMNA P02545 3/20 0.72
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ KDM4E B2RXH2 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ KMT2A Q03164 1/20 0.72
▸ GUSB P08236 1/20 0.65
▸ ADORA3 P0DMS8 1/20 0.65
▸ HPGD P15428 2/20 0.64
▸ MTOR P42345 1/20 0.64
▸ TP53 P04637 1/20 0.62
▸ GAA P10253 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ RUNX1 Q01196 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692551 1.00 CBFB (1.00) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL4812846 0.91 CBFB (0.84) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL25145069 0.88 CBFB (0.79) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL13866537 0.87 NPC1 (0.81) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL15780004 0.86 CBFB (0.75) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL13223456 0.84 NPC1 (1.00) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL30692549 0.83 CBFB (0.78) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL124267 0.83 CBFB (0.78) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL12119033 0.83 CBFB (1.00) CBFBMETAP2METAP1NPC1RAB9A
SCHEMBL124273 0.82 CBFB (0.68) CBFBMETAP2METAP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024451-A Preparation method and application of 2- (2-pyridyl) benzimidazole derivative curcumin copper complex 广西师范大学 2023-11-10 — — CN claimed
CN-117024451-A Preparation method and application of 2- (2-pyridyl) benzimidazole derivative curcumin copper complex 广西师范大学 2023-11-10 — — CN disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 — — US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 — — US disclosed
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2023-06-22 — — US disclosed
WO-2021242790-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF BAYLOR COLLEGE OF MEDICINE (US) 2021-12-02 — — WO disclosed
EP-3670509-A1 INHIBITORS OF INV(16) LEUKEMIA The University of Virginia Patent Foundation (US) 2020-06-24 — — EP disclosed
US-9926290-B2 Inhibitors of INV(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-27 — — US disclosed
US-9926290-B2 Inhibitors of INV(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2018-03-27 — — US disclosed
US-20160096820-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2016-04-07 — — US disclosed
US-9221764-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2015-12-29 — — US disclosed
US-20140243331-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-08-28 — — US disclosed
US-20140243331-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-08-28 — — US disclosed
US-8748618-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-06-10 — — US disclosed
US-8748618-B2 Inhibitors of inv(16) leukemia UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2014-06-10 — — US disclosed
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-03-08 — — US disclosed
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2012-03-08 — — US disclosed
WO-2010132684-A9 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-01-06 — — WO disclosed
WO-2010132684-A2 INHIBITORS OF INV(16) LEUKEMIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-11-18 — — WO disclosed
US-4670402-A Use of benzimidazole derivatives for the detection of blood and other peroxidatically active substances in body fluids and excretion products MACHEREY-NAGEL & CO.-CHEMIKALIENHANDEL (DE) 1987-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059003-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885METAP2 3332/4885METAP1 2810/4885
US-20230192626-A1 NOVEL SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF EPHX1, EPHX2, NCEH1 CBFB 2404/4885METAP2 622/4885METAP1 373/4885
US-20140243331-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885METAP2 3287/4885METAP1 2794/4885
US-20160096820-A1 INHIBITORS OF INV(16) LEUKEMIA FLI1, MCL1, CBFB CBFB 3/4885METAP2 3287/4885METAP1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.